Fasano M B
Bowman Gray School of Medicine, Winston-Salem, North Carolina USA 27157-1042.
Curr Opin Pediatr. 1995 Dec;7(6):688-94. doi: 10.1097/00008480-199512000-00011.
Intravenous immunoglobulin has been used in the treatment of a variety of disorders since the 1970s. Its safety and efficacy, however, have been evaluated in only a minority of these conditions. At present, intravenous immunoglobulin is licensed for use in primary immunodeficiencies, idiopathic thrombocytopenic purpura, chronic lymphocytic leukemia, Kawasaki syndrome, bone marrow transplantation, and pediatric AIDS. Although considered to be a relatively safe product, it is costly and not without risk of adverse reactions, including transmission of infectious agents. This point has been underscored by the recent report of over 100 cases of hepatitis C infection associated with a commercially available intravenous immunoglobulin preparation. Hepatitis C represents the major risk associated with intravenous immunoglobulin, and physicians must carefully weigh both the risks and benefits of this product before initiating treatment in selected patients.
自20世纪70年代以来，静脉注射免疫球蛋白已被用于治疗多种疾病。然而，仅在少数这些病症中对其安全性和有效性进行了评估。目前，静脉注射免疫球蛋白被批准用于原发性免疫缺陷、特发性血小板减少性紫癜、慢性淋巴细胞白血病、川崎病、骨髓移植和小儿艾滋病。尽管被认为是一种相对安全的产品，但它成本高昂且并非没有不良反应的风险，包括传染因子的传播。最近一份关于100多例与一种市售静脉注射免疫球蛋白制剂相关的丙型肝炎感染病例的报告强调了这一点。丙型肝炎是与静脉注射免疫球蛋白相关的主要风险，医生在开始对选定患者进行治疗之前必须仔细权衡该产品的风险和益处。
